Sio Gene Therapies to Participate in Upcoming Investor & Scientific Conferences
March 11 2021 - 8:00AM
Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company
focused on developing gene therapies to radically improve the lives
of patients with neurodegenerative diseases, announced today that
the company will participate in select upcoming investor and
scientific conferences. Details can be found below.
Oppenheimer 31st Annual Healthcare Conference |
Participation: |
Company presentation and 1-on-1 investor meetings |
Presenter: |
Gavin Corcoran, MD, Chief R&D
Officer |
Presentation Date & Time: |
Wednesday, March 17, 2021 at 2:30
PM ET |
Webcast: |
https://wsw.com/webcast/oppenheimer9/siox/2762815 |
|
|
Redburn Gene
Therapy Virtual Summit |
Participation: |
Panel discussion: “Defining a
Gene Therapy Market” |
Presenter: |
Parag V. Meswani, PharmD, Chief
Commercial Officer |
Panel Date & Time: |
Wednesday, March 31, 2021 at 8:00
AM ET |
|
|
Guggenheim
Healthcare Talks: 2021 Genomic Medicines & Rare Disease
Day |
Participation: |
1-on-1 investor meetings |
Date: |
Thursday, April 1, 2021 |
|
|
Gene Therapy
Patient Engagement Summit |
Date: |
March 23-25, 2021 |
About Sio Gene Therapies
Sio Gene Therapies combines cutting-edge science with bold
imagination to develop genetic medicines that aim to radically
improve the lives of patients. Our current pipeline of
clinical-stage candidates includes the first potentially curative
AAV-based gene therapies for GM1 gangliosidosis and
Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal
pediatric conditions caused by single gene deficiencies. We are
also expanding the reach of gene therapy to highly prevalent
conditions such as Parkinson’s disease, which affects millions of
patients globally. Led by an experienced team of gene therapy
development experts, and supported by collaborations with premier
academic, industry and patient advocacy organizations, Sio is
focused on accelerating its candidates through clinical trials to
liberate patients with debilitating diseases through the
transformational power of gene therapies. For more information,
visit www.siogtx.com.
Contacts:
Media
Josephine Belluardo, Ph.D.LifeSci Communications(646)
751-4361jo@lifescicomms.cominfo@siogtx.com
Investors and Analysts
Parag V. MeswaniSio Gene Therapies Inc.Chief Commercial
Officerinvestors@siogtx.com
Sio Gene Therapies (NASDAQ:SIOX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sio Gene Therapies (NASDAQ:SIOX)
Historical Stock Chart
From Jul 2023 to Jul 2024